Document is current

Any future updates will be listed below

Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute

Crossref DOI link: https://doi.org/10.1007/s10549-015-3599-5

Published Online: 2015-10-12

Published Print: 2015-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark